Acura Pharmaceuticals, Inc.
ACUR
$0.02
$0.0191,900.00%
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -34.15% | -54.63% | -40.97% | -41.15% | -69.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.15% | -54.63% | -40.97% | -41.15% | -69.03% |
| Cost of Revenue | -25.82% | -12.36% | 4.65% | -7.53% | 11.61% |
| Gross Profit | -5.50% | -75.39% | -66.05% | -61.85% | -112.69% |
| SG&A Expenses | -8.77% | 7.84% | -25.82% | -13.79% | -16.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.85% | -1.83% | -12.80% | -10.73% | -3.75% |
| Operating Income | 6.02% | -171.26% | -178.92% | -148.70% | -281.67% |
| Income Before Tax | 61.36% | -225.65% | 56.47% | -256.77% | -439.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.36% | -225.65% | 56.47% | -256.77% | -439.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.36% | -225.65% | 56.47% | -256.77% | -439.00% |
| EBIT | 6.02% | -171.26% | -178.92% | -148.70% | -281.67% |
| EBITDA | 6.06% | -163.95% | -151.00% | -133.33% | -243.42% |
| EPS Basic | 83.33% | -194.74% | 56.52% | -253.06% | -433.33% |
| Normalized Basic EPS | 66.41% | -193.33% | -457.14% | -251.61% | -427.50% |
| EPS Diluted | 83.33% | -205.26% | 50.00% | -304.08% | -433.33% |
| Normalized Diluted EPS | 66.41% | -194.92% | -457.14% | -251.61% | -427.50% |
| Average Basic Shares Outstanding | 133.67% | 32.77% | 0.60% | 1.93% | 2.35% |
| Average Diluted Shares Outstanding | 133.67% | 32.04% | 0.60% | 1.93% | 2.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
